Hormonal
GLP-1 and GLP-1/GIP receptor agonists are associated with lower exposure-adjusted mortality rates compared to non-GLP-1 weight management agents.
Beyond weight loss, GLP-1 and GLP-1/GIP agonists may offer a mortality benefit compared to older weight loss drugs. This is a significant advantage for patients with obesity-related comorbidities.
PEY-adjusted RRs confirmed lower mortality risk across most GLP-1 trials... The rate ratios (RRs) for mortality and morbidity were as follows: non-GLP agents (RR: 0.8 and 1.1), WM GLP-1 RAs (RR: 0.7 and 1.4), T2D GLP-1 RAs (RR: 0.7 and 0.9) and GLP-1/GIP RAs (RR: 0.1 and 1.1).
Why this rating
Based on large FDA datasets, but confidence intervals for mortality RRs are wide and often include 1.0, indicating statistical non-significance in many comparisons.
Source
Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects
Aishwarya Prasad et al. · British Journal of Clinical Pharmacology · 2026
DOI 10.1002/bcp.70515
More from this paper
- GLP-1/GIP dual receptor agonists (e.g., tirzepatide) produce significantly greater weight loss than GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and non-GLP-1 agents (e.g., orlistat, phentermine/topiramate) in weight management trials.Good
- Postmarketing reports of neoplasms are higher for GLP-1 RAs compared to non-GLP-1 agents, but remain rare relative to overall exposure.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →